Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flurothyl is a volatile liquid drug from the halogenated ether family, structurally related to inhaled anesthetic agents such as diethyl ether. Unlike its anesthetic relatives, flurothyl acts as a potent central nervous system stimulant and convulsant. Its primary mechanism of action is antagonism of neuronal gamma-aminobutyric acid type A (GABA_A) receptors, leading to inhibition of GABA-mediated inhibitory neurotransmission and resulting in increased neuronal excitability and seizures. Flurothyl was formerly used clinically by inhalation to induce convulsive seizures for the treatment of certain psychiatric illnesses as an alternative to electroconvulsive therapy but is now primarily used in experimental animal models for seizure research[1][2][5][6]. At high concentrations, it may possess general anesthetic properties that are masked by its more potent convulsant effects[1][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on flurothyl.